0000000000981076

AUTHOR

P Pata

showing 3 related works from this author

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

2019

Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery.A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a c…

Malerenal failureTime Factorsmedicine.medical_treatmentAdult; Aged; Anti-Inflammatory Agents Non-Steroidal; Elective Surgical Procedures; Female; Humans; Ileus; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Prospective Studies; Recovery of Function; Time Factors; Treatment Outcome; Colectomy; ProctectomyAnti-Inflammatory Agentscolorectal surgery; ileus; non-steroidal anti-inflammatory drugs; NSAIDSKaplan-Meier Estimate030230 surgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicinePostoperative ComplicationsProspective StudiesProspective cohort studyColectomyColorectalColectomyRISKProctectomyHazard ratioAnti-Inflammatory Agents Non-SteroidalAcute kidney injuryMiddle AgedColorectal surgeryNSAIDTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisFemalePatient SafetyNon-SteroidalCohort studyAdultcolorectal Surgery ileus non-steroidal anti-inflammatory drugsmedicine.medical_specialtyIleusNon‐steroidal anti‐inflammatory drugs. NSAIDs. Postoperative ileus. Colorectal surgery.ACUTE KIDNEY INJURYanti-inflammatory agents03 medical and health sciencesIleusInternal medicinemedicineHumansAdverse effectAgedProportional Hazards Modelsnon-steroidal anti-inflammatory drugs - ileus - colorectal surgeryPostoperative Carebusiness.industryRecovery of Functionmedicine.diseaseSettore MED/18 - Chirurgia Generalecolorectal cancer.Surgerycolorectal surgerybusiness
researchProduct

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct